The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen

European Journal of Gynaecological Oncology

Volumn 35, Issue 5, 2014, Pages 492-498

  Shi, Qingquan ^a   Li, Jinhong ^b   Li, Ming ^a   Wu, Jing ^a   Yao, Qiang ^a   Xing, Aiyun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Endometrial hyperplasia; Endometrial neoplasm; Endometrial polyps; Levonorgestrel releasing intrauterine system (LNG IUS)

Indexed keywords

LEVONORGESTREL; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; ENDOMETRIAL THICKNESS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LONG TERM CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VAGINA BLEEDING; BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; META ANALYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; TAMOXIFEN;

EID: 84908152630     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: 10.12892/ejgot25822014     Document Type: Review

References (34)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials". Lancet, 2005, 365, 1687.
2. Buttini M.J., Jordan S.J., Webb P.M.: "The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: An Australian study and systematic review". Aust. N. Z. J. Obstet. Gynaecol., 2009, 49, 316.
3. Lindahl B., Andolf E., Inqvar C., Ranstam J., Willte R.: "Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma". Anticancer Res., 2008, 28, 1259.
4. Daniel Y., Inbar M., Bar-Am A., Peyser M.R., Lessing J.B.: "The effects of tamoxifen treatment on the endometrium". Fertil. Steril., 1996, 65, 1083.
5. Gottardis M.M., Robinson S.P., Satyawaroop P.G., Jordan V.C.: "Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse". Cancer Res., 1988, 48, 812.
6. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al.: "Tamoxifen for the prevention of breast cancer, current status of the National Surgical Adjuvant Breast and Bowel Project P-l study". J. Natl. Cancer Inst., 2005, 97, 1652.
7. Turbiner J., Moreno-Bueno G., Dahiya S., Sinchez-Estevez C., Hardisson D., Prat J., et al: "Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen". Mod. Pathol., 2008, 21, 925.
8. Patva T., Ranta H., Koivisto A.M., Pylkkanen L., Cuzick J., Holli K.: "A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - A substudy for IBIS I Breast Cancer Prevention Trial". Eur. J. Cancer, 2013, 49, 45.
9. Neven P., Veinaeve H.: "Guidelines for monitoring patients taking tamoxifen treatment". Drug Saf., 2000, 22, 1.
10. Morales L., Timmerman D., Neven P., Konstantinovic M.L., Car-bonez A., Van Huffel S., et al: "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients". Ann. Oncol, 2005, 16, 70.
11. Bertelli G., Hall E., Ireland E., Snowdon C.F., Jassem J., Drosik K., et al.: "Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) - A randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen". Ann. Oncol, 2010, 21, 498.
12. Josefsson M.L., Leinster S.J.: "Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in postmenopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy". Breast, 2010, 19, 76.
13. van de Velde C.J., Rea D., Seynaeve C., Putter H., Hasenbuig A., Van- netzel J.M., et al.: "Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial". Lancet, 2011, 377, 321.
14. Nilsson C.G., Haukkamaa M., Vierola H., Luukkainen T.: 'Tissue concentrations of levonorgestrel in women using a levonorgestrel- releasing IUD". Clin. Endocrinol (Oxf), 1982, 17, 529.
15. Backman T.: "Benefit-risk assessment of the levonorgestrel intrauterine system in contraception". Drug Saf., 2004, 27, 1185.
16. Varma R., Soneja H., Bhatia K., Ganesan R., Rollason T., Clark T.J., Gupta J.K.: "The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia - A long-term follow-up study". Eur. J. Obstet. Gynecol Reprod. Biol, 2008, 139, 169.
17. Wan Y.L., Holland C.: "The efficacy of levonorgestrel intrauterine systems for endometrial protection: A systematic review". Climacteric, 2011, 14, 622.
18. Varma R., Sinha D., Gupta J.K.: "Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) - A systematic enquiry and overview". Eur. J. Obstet. Gynecol Reprod. Biol., 2006, 125, 9.
19. Chin J., Konje J.C., Hickey M.: "Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen". Cochrane Database Syst. Rev., 2009, 4, CD007245.
20. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay HJ.: "Assessing the quality of reports of randomized clinical trials: Is blinding necessary?" Control Clin. Trials., 1996, 17, 1.
21. Altman D.G., Schulz K.F.: "Statistics notes: Concealing treatment allocation in randomised trials". BMJ, 2001, 323, 446.
22. Moher D., Pham B., Jones A., Cook D.J., Jadad A.R., Moher M., et al: "Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?" Lancet, 1998, 352, 609.
23. Higgins J., Green S. (eds): "Cochrane handbook for systematic reviews of interventions 5.1.0 [update March 2011]". The Cochrane Collaboration, 2011. Available at: Http://handbook.cochrane.org.
24. Gardner F.J., Konje J.C., Abrams K.R., Brown L.J., Khanna S., Al- Azzawi F., et al.: "Endometrial protection from tamoxifen-stimu- lated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial". Lancet, 2000, 356, 1711.
25. Chan S.S., Tam W.H., Yeo W., Yu M.M., Ng D.P., Wong A. W., et al.: "A randomized controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women". BJOG, 2007, 114, 1510.
26. Gardner F.J., Konje J.C., Bell S.C., Abrams K.R., Brown L.J., Taylor D.J., Habiba M.: "Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-tenn follow-up of a randomised control trial". Gynecol. Oncol., 2009, 114, 452.
27. Wong A.W., Chan S.S., Yeo W., Yu M.Y., Tam W.H.: "Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen". Obstet. Gynecol., 2013, 121, 943.
28. Kesim M.D., Aydin Y., Atis A., Mandiraci G.: "Long-term effects of the levonoigestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen". Climacteric, 2008, 11, 252.
29. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008". Int. J. Cancer, 2010, 127, 2893.
30. Early Breast Cancer Trialists∗ Collaborative Group: "Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28, 896 women". N. Engl. J. Med., 1988, 319, 1681.
31. Neven P.: "Local levonorgestrel to prevent tamoxifen-related endometrial lesions". Lancet, 2000, 356, 1698.
32. Jones M.E., van Leeuwen F.E., Hoogendoom W.E., Mounts M.J., Hollema H., van Boven H., et al.: "Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries". Breast Cancer Res., 2012, 14, R91.
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): "Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials". Lancet, 2011, 378, 771.
34. Swerdlow A.J., Jones M.E.: "Tamoxifen treatment for breast cancer risk of endometrial cancer a case control study". J. Natl. Cancer Inst., 2005, 97, 375.